Key statistics
On Friday, Lipocine Inc (LPCN:NAQ) closed at 5.15, 116.39% above the 52 week low of 2.38 set on Nov 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.01 |
---|---|
High | 5.20 |
Low | 4.87 |
Bid | 4.89 |
Offer | 5.72 |
Previous close | 5.00 |
Average volume | 15.88k |
---|---|
Shares outstanding | 5.35m |
Free float | 5.19m |
P/E (TTM) | -- |
Market cap | 26.74m USD |
EPS (TTM) | -0.7626 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
- Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session
- Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024
- Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea
- Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results
- Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries
- Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024
- Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference
- Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®
- Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference
More ▼